L. Grunebaum

5.6k total citations · 1 hit paper
82 papers, 3.8k citations indexed

About

L. Grunebaum is a scholar working on Hematology, Internal Medicine and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, L. Grunebaum has authored 82 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Hematology, 26 papers in Internal Medicine and 22 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in L. Grunebaum's work include Venous Thromboembolism Diagnosis and Management (26 papers), Blood Coagulation and Thrombosis Mechanisms (18 papers) and COVID-19 Clinical Research Studies (12 papers). L. Grunebaum is often cited by papers focused on Venous Thromboembolism Diagnosis and Management (26 papers), Blood Coagulation and Thrombosis Mechanisms (18 papers) and COVID-19 Clinical Research Studies (12 papers). L. Grunebaum collaborates with scholars based in France, Switzerland and United States. L. Grunebaum's co-authors include Laurent Sattler, Julie Helms, Ferhat Meziani, Mickaël Ohana, Francis Schneider, François Séverac, Raphaël Clère-Jehl, Ian Léonard-Lorant, Paul‐Michel Mertès and Eduardo Anglés‐Cano and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and Blood.

In The Last Decade

L. Grunebaum

81 papers receiving 3.6k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study

2020 1.9k citations Julie Helms, Charles Tacquard et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
L. Grunebaum	1.7k	919	892	709	608	82	3.8k
Luca Spiezia	641 0.4×	912 1.0×	336 0.4×	396 0.6×	1.3k 2.1×	146	3.4k
Jan–Dirk Studt	1.3k 0.8×	651 0.7×	780 0.9×	562 0.8×	583 1.0×	65	2.8k
Corrado Lodigiani	1.4k 0.8×	800 0.9×	860 1.0×	556 0.8×	254 0.4×	58	2.4k
Doruk Erkan	620 0.4×	467 0.5×	760 0.9×	99 0.1×	3.4k 5.5×	167	7.5k
Anand Padmanabhan	293 0.2×	356 0.4×	405 0.5×	254 0.4×	1.5k 2.4×	70	3.9k
Wolfgang Miesbach	341 0.2×	332 0.4×	202 0.2×	511 0.7×	1.7k 2.7×	192	3.2k
Aurelio Sonzogni	1.1k 0.6×	95 0.1×	593 0.7×	528 0.7×	138 0.2×	102	5.0k
Florian Moik	265 0.2×	1.2k 1.3×	257 0.3×	585 0.8×	267 0.4×	66	2.0k
Rushad Patell	633 0.4×	439 0.5×	218 0.2×	470 0.7×	217 0.4×	115	1.6k
Dimitrios Giannis	1.0k 0.6×	467 0.5×	468 0.5×	567 0.8×	64 0.1×	56	1.8k

Countries citing papers authored by L. Grunebaum

Since Specialization

Citations

This map shows the geographic impact of L. Grunebaum's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L. Grunebaum with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L. Grunebaum more than expected).

Fields of papers citing papers by L. Grunebaum

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L. Grunebaum. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L. Grunebaum. The network helps show where L. Grunebaum may publish in the future.

Co-authorship network of co-authors of L. Grunebaum

This figure shows the co-authorship network connecting the top 25 collaborators of L. Grunebaum. A scholar is included among the top collaborators of L. Grunebaum based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L. Grunebaum. L. Grunebaum is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Godet, Julien, Xavier Delabranche, Laurent Sattler, et al.. (2023). Study of Modifications Induced by Continued Direct Oral Anticoagulant Therapy during Atrial Fibrillation Ablation Procedures on Standard Hemostasis Parameters. Journal of Clinical Medicine. 12(6). 2236–2236. 1 indexed citations

Matsushita, Kensuke, Benjamin Marchandot, Marion Kibler, et al.. (2022). P2Y12 inhibition by clopidogrel increases adverse clinical events after transcatheter aortic valve replacement. International Journal of Cardiology. 360. 53–61. 1 indexed citations

Trimaille, Antonin, Benjamin Marchandot, Walid Oulehri, et al.. (2021). Transient endothelial injury and release of lupus anticoagulant in COVID-19. Archives of Cardiovascular Diseases Supplements. 14(1). 125–126. 1 indexed citations

Trimaille, Antonin, Anaïs Curtiaud, Benjamin Marchandot, et al.. (2021). Venous thromboembolism in non-critically ill patients with COVID-19 infection. Archives of Cardiovascular Diseases Supplements. 13(1). 103–104. 6 indexed citations

Morel, Olivier, Benjamin Marchandot, Laurence Jesel, et al.. (2021). Microparticles in COVID-19 as a link between lung injury extension and thrombosis. ERJ Open Research. 7(2). 954–2020. 5 indexed citations

Trimaille, Antonin, Jecko Thachil, Benjamin Marchandot, et al.. (2020). D-Dimers Level as a Possible Marker of Extravascular Fibrinolysis in COVID-19 Patients. Journal of Clinical Medicine. 10(1). 39–39. 19 indexed citations

Trimaille, Antonin, Anaïs Curtiaud, Benjamin Marchandot, et al.. (2020). Venous thromboembolism in non-critically ill patients with COVID-19 infection. Thrombosis Research. 193. 166–169. 45 indexed citations

Grunebaum, L., François Lévy, Laurent Sattler, et al.. (2018). Adjusted calculation model of heparin management during cardiopulmonary bypass in obese patients. European Journal of Anaesthesiology. 35(8). 613–620. 8 indexed citations

Steib, A., E. Junke, Karim Asehnoune, et al.. (2015). Once versus twice daily injection of enoxaparin for thromboprophylaxis in bariatric surgery: effects on antifactor Xa activity and procoagulant microparticles. A randomized controlled study. Surgery for Obesity and Related Diseases. 12(3). 613–621. 24 indexed citations

10.

Delabranche, Xavier, Julie Helms, Pierre Asfar, et al.. (2014). 0137: Endothelial-derived microparticles contribute to disseminated intravascular coagulopathy during septic shock. Archives of Cardiovascular Diseases Supplements. 6. 24–24. 1 indexed citations

11.

Bidet, Audrey, Dominique Desprez, Emmanuel de Maistre, et al.. (2010). Clinical characteristics and laboratory testing of patients with suspected HIT: A survey on current practice in 11 university hospitals in France. Thrombosis Research. 125(6). e294–e299. 6 indexed citations

12.

Pereira, Bruno, Olivier Morel, L. Grunebaum, et al.. (2008). Facteurs prédictifs de l’existence d’une ischémie myocardique silencieuse chez le patient diabétique. Intérêt de l’évaluation de la surface de l’oreillette gauche. Annales de Cardiologie et d Angéiologie. 57(4). 201–212. 5 indexed citations

13.

Bakouboula, Babé, Olivier Morel, A. Faure, et al.. (2007). Procoagulant Membrane Microparticles Correlate with the Severity of Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine. 177(5). 536–543. 144 indexed citations

14.

Goichot, Bernard, L. Grunebaum, Dominique Desprez, et al.. (2006). Circulating procoagulant microparticles in obesity. Diabetes & Metabolism. 32(1). 82–85. 78 indexed citations

15.

Morel, Olivier, Patrick Ohlmann, Laurence Jesel, et al.. (2005). Variabilité de la réponse plaquettaire au clopidogrel : « résistance » biologique ?. Annales de Cardiologie et d Angéiologie. 54(4). 194–200. 1 indexed citations

16.

Mossard, J. M., R Arbogast, Ronald A. Asherson, et al.. (1994). Variation in von Willebrand's Factor according to the treatment of acute myocardial infarction: physiopathological and clinical implications. European Heart Journal. 15(4). 479–482. 5 indexed citations

17.

Asherson, Ronald A., A. Faradji, L. Grunebaum, et al.. (1992). Hemostatic changes in human adoptive immunotherapy with activated blood monocytes or derived macrophages. Annals of Hematology. 65(2). 75–78. 5 indexed citations

18.

Borg, J.Y., L. Grunebaum, Marc Vasse, et al.. (1991). [Influence of protein S deficiency on the arterial thrombosis risk].. PubMed. 20(22). 1023–7. 14 indexed citations

19.

Salle, C de la, B. Guy, Ronald A. Asherson, et al.. (1991). DNA amplification of HIV genome in hemophiliacs and in newborns from seropositive mothers. Annals of Hematology. 62(5). 165–168. 2 indexed citations

20.

Heitz, A., et al.. (1988). Low dose heparin versus low molecular weight heparin (Kabi 2165, Fragmin®) in the prophylaxis of thromboembolic complications of abdominal oncological surgery. European Journal of Clinical Investigation. 18(6). 561–567. 72 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact